Does a ketogenic diet have beneficial effects on quality of life, physical activity or biomarkers in patients with breast cancer: a randomized controlled clinical trial

Table 3 Quality of life in breast cancer patients before and after intervention in KD group and control group as measured by the EORTC QLQ-C30

Symptoms^a	KD	Control	p-value
Fatigue
Week 0	22(8–33)^a	33(11–44)	0/10
Week 12	33(19–55)	33(33–55)	0/66
p-value	0/01	0/02
Nausea and vomiting
Week 0	0(0–0)	0 (0–20)	0/21
Week 12	0(0–4)	16(0–16)	0/64
p-value	0/01	0/02
Pain
Week 0	16(0–50)	16(0–33)	0/59
Week 12	16(0–50)	33(16–50)	0/59
p-value	0/62	0/38
Reduction in appetite
Week 0	0(0–8)	0(0–33)	0.37
Week 12	33(0–33)	16(0–33)	0.48
p-value	0.02	0.41
Sleep difficulties
Week 0	16(0–33)	0(0–66)	1
Week 12	0(0–41)	33(0–50)	0/81
p-value	0/63	0/88
Dyspnea
Week 0	0(0–33)	0(0–33)	0/31
Week 12	33(0–41)	16(0–33)	0/43
p-value	0.05	0.73
Constipation
Week 0	0 (0–0)	0 (0–33)	0.24
Week 12	0 (0–33)	0 (0–33)	0.51
p-value	0/18	0/39
Diarrhea
Week 0	0 (0–0)	0 (0–0)	0.92
Week 12	0 (0–33)	0 (0–0)	0/65
p-value	0.71	0.20
Financial concerns
Week 0	0 (0–0)	0 (0–0)	0.49
Week 12	0 (0–33)	33 (0–58)	0.28
p-value	0.71	0.01

Mann–Whitney U test was used to compare the continuous variables between the two groups. Wilcoxon was used to compare the continuous variables within the two groups
^aThe higher values indicate a higher grade of symptoms Data shown as median and quartile (25, 75)

ISSN: 1475-2891